EUVIMEDEUVIMED entdecken
Fallbericht

Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report

Neta S Zuckerman, Efrat Bucris, Danielle Keidar-Friedman, Muriel Amsalem, Tal Brosh-Nissimov iD

Clinical Infectious Diseases · 17.02.2024 · 78 (2) · 352-355

DOI: 10.1093/cid/ciad494 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Infectious Diseases, online erschienen am 19.08.2023. Verfasst von Neta S Zuckerman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Central Virology Laboratory, Ministry of Health, Tel Hashomer, Israel. Hauptthemen laut MEDLINE: Ritonavir, Immunocompromised Host. Die Arbeit wurde bisher 102-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance of SARS-CoV-2 to antivirals was shown to develop in immunocompromised individuals receiving remdesivir. We describe an immunocompromised patient who was treated with repeated and prolonged courses of nirmatrelvir and developed de-novo E166V/L50F mutations in the Mpro region. These mutations were associated with clinical and virological treatment failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirImmunocompromised HostHumansMutationSARS-CoV-2Antiviral Agents

Stichwörter der Autor:innen

E166V/L50FMproimmunocompromisednirmatrelvirresistance

Substanzen

RitonavirAntiviral Agents

Autor:innen und Institutionen

  • Central Virology Laboratory, Ministry of Health, Tel Hashomer, Israel.
  • Microbiology Laboratory, Samson Assuta Ashdod University Hospital, Ashdod, Israel.
  • Emerging Infectious Diseases Laboratory, Samson Assuta Ashdod University Hospital, Ashdod, Israel.
  • Infectious Diseases Unit, Samson Assuta Ashdod University Hospital, Ashdod, Israel.
  • Faculty of Health Sciences, Ben Gurion University in the Negev, Beer Sheba, Israel.

ORCID-Profile: Tal Brosh-Nissimov

Zitieren

APA

Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M., & Brosh-Nissimov, T. (2024). Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report. Clinical Infectious Diseases, 78(2), 352-355. https://doi.org/10.1093/cid/ciad494

Vancouver

Zuckerman NS, Bucris E, Keidar-Friedman D, Amsalem M, Brosh-Nissimov T. Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report. Clinical Infectious Diseases. 2024;78(2):352-355. doi:10.1093/cid/ciad494

BibTeX
@article{Zuckerman2024,
  author = {Zuckerman, Neta S and Bucris, Efrat and Keidar-Friedman, Danielle and Amsalem, Muriel and Brosh-Nissimov, Tal},
  title = {Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {2},
  pages = {352--355},
  doi = {10.1093/cid/ciad494}
}
Kostenlos starten →